Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contact Us Login 
An Official Publication of the Indian Association of Oral and Maxillofacial Pathologists


 
  Table of Contents    
ORIGINAL ARTICLE  
Year : 2019  |  Volume : 23  |  Issue : 1  |  Page : 43-48
 

Expression of p63 in tooth germ, dentigerous cyst and ameloblastoma


1 Department of Oral Pathology and Microbiology, Chhattisgarh Dental College and Research Institute, Rajnandgaon, Chhattisgarh, India
2 Department of Oral Pathology and Microbiology, Sharad Pawar Dental College, Wardha, Maharashtra, India
3 Department of Oral Medicine and Radiology, Chhattisgarh Dental College and Research Institute, Rajnandgaon, Chhattisgarh, India

Date of Submission26-May-2018
Date of Acceptance29-Dec-2018
Date of Web Publication17-Apr-2019

Correspondence Address:
Rolly Gupta
Department of Oral Pathology and Microbiology, Chhattisgarh Dental College and Research Institute, Rajnandgaon, Chhattisgarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jomfp.JOMFP_125_18

Rights and Permissions

 

   Abstract 


Context: To assess the role of p63, a p53 homolog, in the cytodifferentiation (odontogenesis) and oncogenesis of odontogenic epithelium.
Aim: The present study aimed to compare the expression pattern of p63 in the epithelium of tooth germ, dentigerous cyst (DC) and ameloblastoma (AB).
Materials and Methods: Tissue specimens of thirty tooth germs, thirty ABs and thirty DCs were examined by immunohistochemistry for the expression of p63. Results: p63 labeling index (LI) was observed in descending order in epithelial cells of ABs, tooth germs and DCs. p63 LI was statistically nonsignificant among all the three groups. ABs revealed the highest p63 expression, but, surprisingly, tooth germs showed higher expression than DCs.
Conclusion: p63 plays a role in the cytodifferentiation and proliferation of odontogenic epithelial cells irrespective of the tissue (normal developing or lesional tissue). This implies that p63 cannot be used as a diagnostic marker. However, our results indicate p63 overexpression as a mark of increased proliferation. Thus, it can be stipulated that p63 can be used as a prognostic marker in odontogenic lesions with more aggressive and invasive phenotype. Our results also suggest the differential function of p63 in both developing and lesional odontogenic tissues, which, however, depends on p63 isoform predominantly being expressed. Therefore, identification of p63-predominant isoform in a particular lesion is more important than the presence or absence of p63. Consequently, we suggest the performance of polymerase chain reaction analysis along with immunohistochemical evaluation in further studies.


Keywords: Cytodifferentiation, labeling index, odontogenic lesion, oncogenesis


How to cite this article:
Gupta R, Chaudhary M, Patil S, Fating C, Hande A, Suryawanshi H. Expression of p63 in tooth germ, dentigerous cyst and ameloblastoma. J Oral Maxillofac Pathol 2019;23:43-8

How to cite this URL:
Gupta R, Chaudhary M, Patil S, Fating C, Hande A, Suryawanshi H. Expression of p63 in tooth germ, dentigerous cyst and ameloblastoma. J Oral Maxillofac Pathol [serial online] 2019 [cited 2019 May 23];23:43-8. Available from: http://www.jomfp.in/text.asp?2019/23/1/43/256418





   Introduction Top


Odontogenic lesions are remarkable among oral lesions because of their clinical and histological heterogeneity. This diversity is reflected as there is complex development of dental structures. Odontogenic lesions are derived from aberrations in odontogenesis or the cell remnants of odontogenic apparatus are common source of odontogenic lesions within the jawbones. Among odontogenic lesions, dentigerous cysts (DCs) are one of the most common developmental odontogenic cysts, making up to 16.6% of all jaw cysts,[1] and ameloblastomas (ABs) are the neoplasms that account for ~1% of all other oral tumors.[2]

ABs deserve special attention because of their particular complex biologic behavior, exhibiting great infiltrative potential and high recurrence.[3],[4] Several recent studies have detected genetic and cytogenetic alterations in these epithelial odontogenic lesions; however, the detailed mechanism of aberration in odontogenesis, oncogenesis, cytodifferentiation and tumor progression remains unknown.[5],[6] p53 gene is a well-recognized tumor suppressor gene that is frequently altered in cysts[1] and tumors.[7],[8] p63 gene, a p53 homolog, has been identified at loci 3q27–29.[9],[10],[11] p63 gene encodes multiple proteins that have a significant degree of sequence homology, particularly in the transactivation, DNA binding and oligomerization domains.[9],[10],[11],[12] Isoforms derived from two different promoters are named TA and Δ N isoforms. TA isoforms (TAp63) containing the transactivation domain are capable of transactivating p53 target genes and inducing growth arrest or cell death, whereas Δ N isoforms (Δ Np63) lacking the transactivation domain exert a dominant negative effect on their TA isoforms and wild-type p53 by blocking their transactivation.[11],[12] Although p63 might have a tumor suppressor function, genetic alterations, such as mutation and loss of heterozygosity, are less frequent than those associated with p53.[11],[12],[13],[14]

Previous immunohistochemical studies done in tooth germs and ABs using p53 antibody suggest that the p53 signaling cascade has an important role in the cytodifferentiation (odontogenesis) and oncogenesis of odontogenic epithelium.[15] Several syndromes associated with p63 gene mutations have shown tooth abnormalities of both primary and permanent dentition as one of the features.[16],[17] Keeping two things in mind that p63 belongs to p53 tumor suppressor gene family and has association with syndromes showing tooth abnormalities, the present study was planned to know whether p63 is also having a similar role as p53 gene. In recent studies, the expression of p63 has been demonstrated in odontogenic cysts.[18],[19],[20] In one study, the expression of p63 was examined in ABs.[21] No immunohistochemical study has been performed in tooth germs, DCs and ABs together using p63 antibody. In the present study, the expression of p63 in tooth germs, DCs and ABs was examined by immunohistochemistry (IHC) to clarify its role in normal odontogenesis and in cases of aberration in odontogenesis, i.e., in odontogenic lesions.


   Materials and Methods Top


A descriptive observational study was carried out from August 2009 for 2 years in the Department of Oral Pathology and Microbiology, Sharad Pawar Dental College and Hospital, Datta Meghe Institute of Medical Sciences (deemed to be university), Sawangi (M), Wardha, Maharashtra, India. The study protocol was approved by the Institutional Ethical Committee. The study included histopathologically diagnosed thirty cases of tooth germs, thirty cases of DCs and thirty cases of ABs. ABs constituted of histological subtypes of 10 cases of follicular ABs and 10 cases of plexiform ABs, five cases of acanthomatous ABs, three cases of basal cell ABs and two cases of desmoplastic ABs. IHC was performed on paraffin-embedded tissues fixed in 10% neutral-buffered formalin. The sections were cut serially to 5 μm of thickness for immunohistochemical staining. After immunostaining, p63 immunolabeling was assessed in all the tissue sections for immunopositivity, type of staining (whether weak or strong) and analyzing layers showing dense immunopositivity.

Immunohistochemical method for the detection of p63 antigen

The tissue sections were deparaffinized. For IHC, Streptavidin-Biotin Detection System HRP-DAB (product code: RE7110K, Novo-castra kit) was employed as peroxidase detection system. Blocking of endogenous peroxidase activity was done by treating hydrated sections with 3% H2O2 in methanol for 30 min. Then, antigen retrieval was done by applying 0.01 M sodium citrate buffer (pH 6.0) over the sections. Then, the slides were heated in a microwave oven for 10 min and bench cooled for 20 min, and again the same cycle was repeated. To prevent nonspecific reactions, sections were incubated with 10% serum for 10 min. Prediluted p63 antibody (clone p63 BC4A4; product code: Sc-56188, Santa Cruz Biotechnoloy Inc.,) was incubated at room temperature in a humidifying chamber for 60 min and then at 4°C overnight. One section from each positive control was used as the negative control by incubating with nonimmune serum instead of primary antibody. Then, incubation with secondary biotinylated antibody and streptavidin-peroxidase reagent at room temperature in a humidifying chamber for 30 min was done. Freshly prepared substrate/chromogen solution of 3,3'-diaminobenzidine (mix 5 ml of concentrated 3,3'-diaminobenzidine in 50 ml of substrate buffer) was applied to visualize the antigen–antibody reaction. Finally, the sections were counterstained with Mayer's hematoxylin. Sections were examined by conventional light microscopy (Leica microscope with image analyzer LEICA QWIN standard).

Assessment of immunohistochemically stained sections

The cells were scored p63 immunopositive only if nucleus stained brown, i.e., only when intranuclear DAB staining was observed. Cells that lacked nuclear staining or a clear nucleus were excluded. All the stained nuclei were scored positive regardless of the intensity of their staining. A minimum of 1000 cells were counted in each section. Tissue sections were scanned at ×100 magnification for most heavily immunolabeled p63-positive cells in the epithelium. The cell counts were made in ten randomly selected fields on captured image at ×400 magnification with conventional light microscope. The counting was done by two observers, and the mean was taken as a final count. The number of positively stained nuclei was counted and expressed as a percentage of the total number. The index of positivity, i.e., labeling index (LI), was obtained for p63 protein expression for all the groups as follows:

p63 LI = Number of IHC-positive cells for p63 × 100/total number of cells observed.

Statistical analysis

Group mean for p63 LI was derived for each group [Table 1]. The data were analyzed statistically using SPSS software version 16.0 for Windows. Pearson's correlation test was applied. The level of statistical significance was at P < 0.05.
Table 1: p63 labeling index in all groups: Descriptive statistics

Click here to view



   Results Top


p63 labeling index

p63 antigen was expressed in 100% of tooth germs, 100% of DCs and 100% of ABs. In tooth germs, almost complete epithelium showed dense p63 immunolabeling [Figure 1]a and [Figure 1]b. In DCs, strong and dense p63 immunolabeling was seen in the basal and parabasal layers, and the absence of staining was seen in most part of the superficial layer of epithelium [Figure 1]c. In ABs, p63 immunoreactivity was dense predominantly in the peripheral cells of the ameloblastic follicle among all of the histologic variants [Figure 1]d,[Figure 1]e,[Figure 1]f,[Figure 1]g. Fewer central cells of ameloblastic follicle of all variants showed staining. Keratinizing cells showed markedly decreased reactivity for p63 in acanthomatous ABs [Figure 1]h. Basal cell ABs exhibited p63 reactivity in most neoplastic cells [Figure 1]i.
Figure 1: Photomicrograph of immunostaining for p63 (a) Bud stage – p63 immunostaining (×400). (b) Advanced bell stage – p63 immunostaining (×40). (c) Dentigerous cyst – p63 immunostaining (×400). (d) Follicular ameloblastoma – p63 immunostaining (×100). (e) Follicular ameloblastoma – p63 immunostaining (×400). (f) Plexiform ameloblastoma with areas of follicular ameloblastoma – p63 immunostaining (×40). (g) Plexiform ameloblastoma – p63 immunostaining (×400). (h) Acanthomatous ameloblastoma – p63 immunostaining (×400). (i) Basal cell ameloblastoma – p63 immunostaining (×100)

Click here to view


Statistically, a nonsignificant difference of p63 LI was noted among ABs, DCs and tooth germs [Table 2]. p63 LI was observed in descending order in ABs, tooth germs and DCs [Table 1]. However, the correlation of p63 LI was higher in AB than DC (P = 0.525) and tooth germs (P = 0.431). Surprisingly, the correlation of p63 LI was higher in tooth germs than DC (P = 0.795) [Table 2].
Table 2: Pearson's correlation coefficient

Click here to view



   Discussion Top


The discovery of p63, a p53 homolog, has fueled new insights and exposed enigmas in the understanding of the dramatic tumor suppressor gene family. p63 plays a major role in the maintenance of epithelial stem cells, as well as in their terminal differentiation rather than tumor suppression.[18],[19] p63 protein is found restricted to cells with high proliferative potential and is absent from cells undergoing terminal differentiation.[22]

Recently, p63 has been proposed to be a specific marker for precursor/stem cells in many epithelial tissues and could be considered as a marker for assessing the proliferative activity of the cell.[18] It was seen that, in the absence of p63, stem cells and their progenies die by apoptosis, and the crippled stem cells are unable to carry cell proliferation and self-renewal function.[19] Mutations of p63 gene have recently been shown to cause several inherited human syndromes with abnormal limb development and/or ectodermal dysplasia, such as ectrodactyly, facial cleft syndrome, ankyloblepharon and clefting syndrome, acro-dermato-ungual-lacrimal-tooth syndrome and limb-mammary syndrome, which often accompany abnormal tooth development ranging from enamel dysplasia to a tooth loss.[13],[16],[17] The authors of the present study report that tooth germ develops from both epithelial and mesenchymal components, and aberration in odontogenesis leads to the emergence of the odontogenic lesions. The authors further state that the extent of the penetrance of aberrancy in odontogenic apparatus gives rise to the prevailing heterogenicity in odontogenic lesions, i.e., odontogenic cyst or odontogenic tumor. The exact mechanism for aberrancy or how many factors are involved or what decides that whether a cyst will be formed or a tumor is still unknown. However, we hypothesize that mild aberrations to odontogenic apparatus lead to the formation of odontogenic cyst such as DC, whereas greater degree of aberration leads to the development of odontogenic tumors such as AB, on the basis of their clinical behavior. An extensive research in this context is needed to be taken up. In the present study, IHC for p63 was employed among tooth germs, DCs and ABs to evaluate its role in the differentiation, proliferation and oncogenesis of odontogenic epithelial cells. Our study also aimed to evaluate the proliferative potential and aggressive behavior of odontogenic lesions (DC and AB) when compared with tooth germs.

In the present study, tooth germs immunohistochemically showed p63 expression, in epithelial components, suggesting that p63 is involved in epithelial differentiation during tooth development. Almost the complete epithelium of tooth germ showed p63 expression, reflecting high proliferative activity occurring during its development [Figure 1]a and [Figure 1]b. Our finding is in accordance with the concept that tooth germ is dynamic with regard to its higher epithelial turnover rate and subsequent differentiation process.

In DC, strong and dense p63 immunolabeling is seen in the basal and parabasal layers, and absence of staining is seen in most part of superficial layer; these results were in accordance with those of other studies [Figure 1]c.[18],[20] p63 is critical for the stem cell compartment, so strong staining is seen in basal and parabasal layers. p63 is least or not present in the differentiated cells, so no expression could be seen in the superficial layer of DC which is central for terminal differentiation. This type of staining in DC could indicate the normal wild-type p63 protein expression, related to apoptosis and cell proliferation, thus maintaining the regular 2–3 cell layer thickness of epithelium. Thus, it can be concluded that the mechanism of expansion of DC could be some distinct factors other than the epithelial proliferation which is often the probable cause of expansion for other cysts. This is confirmed by the lack of increased proliferative activity in lining the epithelium of DC.

In ABs, densely p63-positive cells were mainly located in the peripheral cells of neoplastic islands, whereas fewer central cells showed immunoreactivity; these results were in accordance with those of a previous study.[21] The results of the present study might indicate that p63 abnormalities (i.e., overexpression) can play a crucial role in early neoplastic transformation (oncogenesis) during the development of Abs, a similar concept was put forth in a previous study.[21] Increased immunoreactivity of p63 only in the peripheral cells of neoplastic islands of ABs could suggest its locally invasive biological behavior.

In the present study, p63 LI was found highest in ABs than DC and tooth germ [Table 1]. However, nonsignificant difference of p63 LI was observed among ABs, DCs and tooth germs. An interesting finding of the present and previous studies was that the proliferating markers were observed predominantly in peripheral cells of tumor islands of ABs.[23],[24],[25],[26],[27] This could explain the locally infiltrating growth of ABs. Other previous studies have noted higher and nonsignificant difference of mean labeling indices of proliferative markers, for example, PCNA and Ki-67, in ABs and DCs.[4],[26],[28] The higher proliferative activity along with aggressive infiltrating nature of ABs as well as different morphology between DCs and ABs facilitates more difficulty in surgical accessibility in ABs than DCs though both are odontogenic lesions. This could suggest the recurrence and worse prognosis for ABs than DCs. In the present and previous studies, the keratinizing cells of acanthomatous AB did not show p63 immunoreactivity, whereas p63 immunoreactivity was slightly higher in basal cell AB than that in other subtypes [Figure 1]h and [Figure 1]i.[21] In acanthomatous ABs, there was absence of staining in the keratinizing cells as they are the differentiated compartment. Basal cell ABs show higher expression of some apoptotic inhibitory factors, including Bcl-2, Bcl-x and survivin, than other subtypes, and this AB variant is considered to possess a high potential for cell survival.[21]

As for ABs, the present study results were in accordance with those of other studies which have found nonsignificant differences of proliferative activity among the different histological subtypes of ABs.[25],[26],[27],[28] This may suggest that the histological subtype of Ameloblastoma does not have any significant effect on prognosis. Future studies should be carried out by using a large number of cases of each histological subtype of Ameloblastoma.

In the present study, a nonsignificant difference of p63 LI was observed between tooth germ and DC. Surprisingly, in tooth germ, p63 LI was found higher than that of DC but lower than that of AB. As tooth germ is a developing odontogenic tissue, it has higher proliferative activity which is indicated by an increased p63 LI. Although tooth germ is dynamic, it maintains regular thickness of fetal epithelium, suggesting balanced cellular proliferation and apoptosis. Lower p63 LI in DC indicates lack of increased proliferative activity in lining epithelium, and this is confirmed by the fact that DC maintains regular 2–3 cell layer thickness of epithelium.

However, the highest p63 LI in AB than tooth germ and DC indicates the greatest proliferative potential of ABs because of its neoplastic nature. Hence, it could be stipulated that, in ABs, apart from the proliferative compartment deciding the p63 LI, more importantly, p63 might have a role in the oncogenesis or malignant transformation of odontogenic epithelium, thus increasing the p63 immunoreactivity.

While p53 gene is mutated in more than 50% of human cancers, mutations of its homolog p63 gene are infrequent.[21] Thus, it could be stipulated that not the mutated form but one of the isoforms of wild-type p63 may play oncogenic role. Recently, Δ Np63 amplification and/or overexpression has been identified in human malignancies, including nasopharyngeal, bladder, prostate, skin and esophageal carcinomas. These features support the notion that Δ Np63 plays an oncogenic role in human tumors.[21] Thus, it could be hypothesized that Δ Np63 isoform might play a role in the oncogenesis of odontogenic epithelium, which was in accordance with the previous results.[21]

To confirm this hypothesis, extensive study with larger sample size and all kinds of odontogenic lesions must be taken into account for IHC along with the other advanced diagnostic modalities, for example, polymerase chain reaction (PCR).


   Conclusion Top


The expression of p63 in tooth germs, DCs and ABs suggests that this p53 homolog plays a role in the differentiation and proliferation of odontogenic epithelial cells. Hence, it could be stipulated that p63 can be used as a prognostic marker in odontogenic lesions. In addition, variations of expressed p63 isoforms suggest that p63 might differentially function in both developing and neoplastic odontogenic tissues, which further needs to be assessed by PCR technique.

Acknowledgments

The authors extend their sincere thanks to Prof. Dr. Amol Gadbail and Mr. Rupesh Maladhary, laboratory technician, Department of Oral and Maxillofacial Pathology, Sharad Pawar Dental College and Hospital, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, Maharashtra, India, and Acharya Vinobha Bhave Rural Hospital Sawangi (Meghe), Wardha, Maharashtra, India. The authors sincerely acknowledge the contribution of Dr. Madhuri Gawande, Department of Oral Pathology and Microbiology, Sharad Pawar Dental College, Wardha, Maharashtra, India in the study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Shear M. Dentigerous cyst In: Shear M. editor. Cysts of the Oral Regions. 3rd ed. Oxford: Butterworth-Heinemann; 1992. p. 75-98.  Back to cited text no. 1
    
2.
Barnes L, Eveson JW, Reichart PA, Sidransky D, editors. World Health Organization Classification of Tumours: Pathology and Genetics Head and Neck Tumours. Lyon, France: IARC Press; 2005. p. 306-07.  Back to cited text no. 2
    
3.
Pinheiro JJ, Freitas VM, Moretti AI, Jorge AG, Jaeger RG. Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activity. Histopathology 2004;45:65-72.  Back to cited text no. 3
    
4.
Regezi JA. Odontogenic cysts, odontogenic tumors, fibroosseous, and giant cell lesions of the jaws. Mod Pathol 2002;15:331-41.  Back to cited text no. 4
    
5.
Heikinheimo K, Jee KJ, Niini T, Aalto Y, Happonen RP, Leivo I, et al. Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res 2002;81:525-30.  Back to cited text no. 5
    
6.
Jääskeläinen K, Jee KJ, Leivo I, Saloniemi I, Knuutila S, Heikinheimo K, et al. Cell proliferation and chromosomal changes in human ameloblastoma. Cancer Genet Cytogenet 2002;136:31-7.  Back to cited text no. 6
    
7.
Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.  Back to cited text no. 7
    
8.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.  Back to cited text no. 8
    
9.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-19.  Back to cited text no. 9
    
10.
Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-43.  Back to cited text no. 10
    
11.
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, et al. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-16.  Back to cited text no. 11
    
12.
Marin MC, Kaelin WG Jr. P63 and p73: Old members of a new family. Biochim Biophys Acta 2000;1470:M93-100.  Back to cited text no. 12
    
13.
Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L, et al. Complex transcriptional effects of p63 isoforms: Identification of novel activation and repression domains. Mol Cell Biol 2002;22:8659-68.  Back to cited text no. 13
    
14.
Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999;59:4165-9.  Back to cited text no. 14
    
15.
Kumamoto H, Izutsu T, Ohki K, Takahashi N, Ooya K. P53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas. J Oral Pathol Med 2004;33:292-9.  Back to cited text no. 15
    
16.
Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell 1999;99:143-53.  Back to cited text no. 16
    
17.
Brunner HG, Hamel BC, Van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002;39:377-81.  Back to cited text no. 17
    
18.
Atarbashi Moghadam S, Atarbashi Moghadam F, Mokhtari S, Eini E. Immunohistochemical analysis of P63 expression in odontogenic lesions. Biomed Res Int 2013;2013:624176.  Back to cited text no. 18
    
19.
Dong Q, Pan S, Sun LS, Li TJ. Orthokeratinized odontogenic cyst: A clinicopathologic study of 61 cases. Arch Pathol Lab Med 2010;134:271-5.  Back to cited text no. 19
    
20.
Seyedmajidi M, Shafaee S, Shafigh E, Bijani A, Hamidi H. P63 expression in randomized odontogenic cysts. Saudi Med J 2011;32:463-6.  Back to cited text no. 20
    
21.
Kumamoto H, Ohki K, Ooya K. Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med 2005;34:220-6.  Back to cited text no. 21
    
22.
Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999;113:1099-105.  Back to cited text no. 22
    
23.
Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, Almeida OP, Carrasco-Daza D, Garcia-Vazquez F, et al. Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol 2008;44:805-11.  Back to cited text no. 23
    
24.
Meer S, Galpin JS, Altini M, Coleman H, Ali H. Proliferating cell nuclear antigen and Ki67 immunoreactivity in ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:213-21.  Back to cited text no. 24
    
25.
Migaldi M, Sartori G, Rossi G, Cittadini A, Sgambato A. Tumor cell proliferation and microsatellite alterations in human ameloblastoma. Oral Oncol 2008;44:50-60.  Back to cited text no. 25
    
26.
Piattelli A, Fioroni M, Santinelli A, Rubini C. Expression of proliferating cell nuclear antigen in ameloblastomas and odontogenic cysts. Oral Oncol 1998;34:408-12.  Back to cited text no. 26
    
27.
Sandra F, Mitsuyasu T, Nakamura N, Shiratsuchi Y, Ohishi M. Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma. Oral Oncol 2001;37:193-8.  Back to cited text no. 27
    
28.
Slootweg PJ. P53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 1995;24:393-7.  Back to cited text no. 28
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
            

    

 
   Search
 
  
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Article in PDF (1,837 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed120    
    Printed0    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal

Journal of Oral and Maxillofacial Pathology | Published by Wolters Kluwer - Medknow
Online since 15th Aug, 2007